Treatment-based subgroups of low back pain: a guide to appraisal of research studies and a summary of current evidence.

Best Pract Res Clin Rheumatol

The George Institute for International Health, University of Sydney, PO Box M201, Missenden Rd, Camperdown, NSW 2050, Australia.

Published: April 2010

There has been a recent increase in research evaluating treatment-based subgroups of non-specific low back pain. The aim of these sub-classification schemes is to identify subgroups of patients who will respond preferentially to one treatment as opposed to another. Our article provides accessible guidance on to how to interpret this research and determine its implications for clinical practice. We propose that studies evaluating treatment-based subgroups can be interpreted in the context of a three-stage process: (1) hypothesis generation-proposal of clinical features to define subgroups; (2) hypothesis testing-a randomised controlled trial (RCT) to test that subgroup membership modifies the effect of a treatment; and (3) replication-another RCT to confirm the results of stage 2 and ensure that findings hold beyond the specific original conditions. At this point, the bulk of research evidence in defining subgroups of patients with low back pain is in the hypothesis generation stage; no classification system is supported by sufficient evidence to recommend implementation into clinical practice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.berh.2009.11.003DOI Listing

Publication Analysis

Top Keywords

treatment-based subgroups
12
low pain
12
evaluating treatment-based
8
subgroups patients
8
clinical practice
8
subgroups
5
subgroups low
4
pain guide
4
guide appraisal
4
appraisal studies
4

Similar Publications

The effect of estimating prevalences on the population-wise error rate.

Stat Methods Med Res

January 2025

Institute for Statistics and Competence Center for Clinical Trials, University of Bremen, Bremen, Germany.

The population-wise error rate is a type I error rate for clinical trials with multiple target populations. In such trials, a treatment is tested for its efficacy in each population. The population-wise error rate is defined as the probability that a randomly selected, future patient will be exposed to an inefficient treatment based on the study results.

View Article and Find Full Text PDF

Background: The efficacy of 5-aminosalicylic acid (5-ASA) in combination with advanced therapies (ADTs), particularly ustekinumab (UST), for the treatment of inflammatory bowel disease (IBD) remains unclear.

Methods: This retrospective cohort analysis used data from the Medical Data Vision database, including patients with ulcerative colitis (UC) and Crohn's disease (CD) who had initiated UST therapy. Cumulative UST continuation rates and factors associated with UST failure were analyzed, and post hoc subgroup analyses based on prior ADT use were conducted.

View Article and Find Full Text PDF
Article Synopsis
  • Alzheimer's disease (AD) is a major, incurable form of dementia, and recent research highlights the role of a new cell death process called PANoptosis, which combines pyroptosis, apoptosis, and necroptosis.
  • * This study identifies different molecular subtypes of AD by analyzing PANoptosis-related genes through various datasets and statistical methods, suggesting potential new therapeutic targets for treatment.
  • * Results showed 24 differentially expressed PANoptosis genes, resulting in two distinct AD subgroups, which revealed differences in disease progression and potential therapeutic hub genes linked to early synaptic dysfunction.
View Article and Find Full Text PDF

Background: Use of serum procalcitonin (PCT), an inflammatory biomarker for bacterial infections, has shown promising results for early stopping antibiotic treatment among patients with respiratory infections and sepsis. There is need for additional data regarding effectiveness and safety of this concept among patients with cancer.

Methods: Individual data of patients with a documented diagnosis of cancer and proven or suspected respiratory infection and/or sepsis were extracted from previous trials where adult patients were randomized to receive antibiotic treatment based on a PCT protocol or usual care (control group).

View Article and Find Full Text PDF

Background: Following surgery, patients with newly diagnosed glioblastoma frequently enter clinical trials. Nuanced risk assessment is warranted to reduce imbalances between study arms. Here, we aimed (I) to analyze the interactive effects of residual tumor with clinical and molecular factors on outcome and (II) to define a postoperative risk assessment tool.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!